Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03990571 · ClinicalTrials.gov registry record · Phase 2
Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
A Phase 2 study of Metastatic Adenoid Cystic Carcinoma and Recurrent Adenoid Cystic Carcinoma, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT03990571 is a Phase 2 study of Metastatic Adenoid Cystic Carcinoma and Recurrent Adenoid Cystic Carcinoma that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 40 participants, below the 45-participant average among 4 other Metastatic Adenoid Cystic Carcinoma trials with a reported enrollment target (11% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03990571, a Phase 2 study of Metastatic Adenoid Cystic Carcinoma and Recurrent Adenoid Cystic Carcinoma, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well axitinib and avelumab work in treating patients with adenoid cystic carcinoma that has come back or spread to other places in the body. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving axitinib and avelumab together may help to control adenoid cystic carcinoma.
Conditions Studied
Interventions
- DRUG Axitinib
- DRUG Avelumab
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2019-07-22 |
| Est. Completion | 2023-03-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03990571
The ClinicalTrials.gov registry entry for NCT03990571 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 45-participant average among 4 other Metastatic Adenoid Cystic Carcinoma trials with a reported enrollment target (11% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Metastatic Adenoid Cystic Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Axitinib is the first listed.
NCT03990571 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT03990571 about?
NCT03990571 is a clinical study titled "Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma". This phase II trial studies how well axitinib and avelumab work in treating patients with adenoid cystic carcinoma that has come back or spread to other places in the body. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclon...
What is the current status of trial NCT03990571?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2019-07-22. Estimated completion is 2023-03-20.
What conditions does trial NCT03990571 study?
This clinical trial studies the following conditions: Metastatic Adenoid Cystic Carcinoma, Recurrent Adenoid Cystic Carcinoma, Progressive Disease.
What interventions are being tested in trial NCT03990571?
The interventions under investigation include: Axitinib (DRUG), Avelumab (DRUG).
Who is sponsoring clinical trial NCT03990571?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03990571 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Adenoid Cystic Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC
RECRUITING · Phase 1
-
Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma
RECRUITING · Phase 1
-
Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: The SOLAR Trial
RECRUITING · NA
-
AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Metastatic Adenoid Cystic Carcinoma
All registered trials for this condition
Recurrent Adenoid Cystic Carcinoma
All registered trials for this condition
Texas
All trials with a study site in Texas
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.